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Jonathan Ewbank received his
Ph.D. training in biophysics with
Tom Creighton in the MRC LMB in
Cambridge and the EMBL in
Heidelberg. After a productive
spell in Ulrich Hartl’s lab, then at
the Sloan Kettering Laboratory in
New York, working on the
interaction of folding proteins and
chaperones, he switched fields to
do a post-doc with Siegfried
Hekimi at McGill University in
Montreal, studying the timing gene
clk-1 of the nematode
Caenorhabditis elegans. He then
moved to the Centre
d’Immunology de Marseille
Luminy (CIML) in 1997 to work on
cellular microbiology with Jean-
Pierre Gorvel. In 1999, he started
his own group at the CIML and
has subsequently focused on
host–pathogen interactions using
C. elegans as a model.
What turned you on to research
in the first place? I was lucky
enough to have had the chance to
work in the R&D department of G.
D. Searle (now defunct) for a year
before starting an undergraduate
degree. This was in 1983 when the
large-scale production of
recombinant proteins was
becoming a reality. It was an
exciting time. I worked with an
enthusiastic group of people, and
shared the real thrill that
occasionally comes when a
significant advance is made. The
department used to invite
academic speakers on a regular
basis and one was Tom Creighton.
He gave a great talk on
understanding (or rather not
understanding) the basis of protein
folding. I was hooked and five
years later started a PhD under his
supervision at the MRC LMB.
What is the best advice you’ve
been given? One of the scientists
at Searle, Helmut Sassenfeld, said
that it’s only worth doing research
if it “gives you a buzz”. I say the
same thing to students who come
to see me, that they need to have
a real enthusiasm and curiosity for
a subject. It’s the only way to get
through the fallow periods and
frustrations that invariably
accompany any project.
What has been your biggest
mistake in research? While trying
to clone a gene that’s involved in
biological timing in C. elegans, after
several months of fruitless efforts, I
had a first encouraging result. As I
went further, more and more signs
suggested that it was a false lead,
but I wanted so much for the first
result be to real and came up with
more and more obtuse reasons to
explain the increasing number of
inconsistencies. In the end, there
was the inescapable conclusion
that I’d been chasing the wrong
gene. A year of work just swept
away. This has taught me, I hope,
to be less stubborn, but I still have
a tendency to try to go too fast.
Fortunately I now work with my
wife, whose rigour counterbalances
my impetuosity. Nathalie never
hesitates to point out when my
ideas are on shaky ground!
Do you have a ‘scientific hero’?
Collectively, the MRC LMB.
Almost everyone I came into
contact there was remarkably
open to discussion with the
students. You could come away
from the cafeteria with your head
spinning with ideas. Students
were expected to have ideas of
their own and be able to defend
them. And added to that was the
emphasis on technological
development, with a great support
staff, which meant that one felt
that one had access to the best
possible tools.
What are the big questions that
remain to be answered in your
field? Can one really model the
evolution and dynamics of
host–pathogen interactions at the
individual and population levels,
and can this lead to better
strategies for combating the
emergence of future diseases. I
adhere to the idea that, within the
next 20 or 30 years, at least one
very nasty pathogen — much
worse than SARS and more likely
natural than man-made — will
sweep the globe. Defoe’s ‘Journal
of the plague years’ still makes
salutary reading.
Why do you work in France? I
always found attractive the French
model of permanent government-
funded posts for technicians and
researchers at all levels. In an
ideal situation, this can encourage
long-term and high-risk projects.
Sadly, the emphasis is more and
more on research with direct
practical application. In my
opinion, this is woefully
shortsighted and comes at a time
when other countries are again
realising the value of high quality
basic research. Although it’s
increasingly difficult to obtain
these fixed posts, they also give a
stability that’s conducive to family
life. And lastly, there was the
opportunity to work at the CIML, a
very dynamic institute, and live in
Marseille where the quality of life
is excellent.
You’ve a ‘Science and Society’
part to your webpage: why?
I’ve been interested in the impact
on society of molecular biology
since being an undergraduate. At
the LMB we had a graduate
student journal club, and after a
talk on some of the potential
problems, one of my fellow
students said, “why bother
discussing this; it’s all going to
happen anyway”. I don’t agree.
There are enormous financial
pressures pushing research in
certain directions, but these can
be resisted. I recently heard John
Sulston give an excellent talk
where he called for a more open
research ethos that could counter
some of the problems that arise
when the stakes become so high.
I sometimes get the impression
that researchers take the view
“well that’s OK, someone else is
thinking about these issues, I can
just carry on with my work”. In my
view, these issues should be an
integral part of science
education. Luckily there are more
and more initiatives like the
annual EMBO Science and
Society meetings that bring
together the interested parties,
and increase awareness of the
issues at stake.
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